Clinical Infectious Diseases 2007;44:1115–1122
© 2007 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2007/4408-0019$15.00
DOI: 10.1086/512816
HIV/AIDS MAJOR ARTICLE
The Effect of Antiretroviral Therapy on Secondary Transmission of HIV among Men Who Have Sex with Men
Alethea W. McCormick,1
Rochelle P. Walensky,3,4,5,6
Marc Lipsitch,1
Elena Losina,6,7
Heather Hsu,3
Milton C. Weinstein,2
A. David Paltiel,8
Kenneth A. Freedberg,2,3,4,6,7 and
George R. Seage III1
Departments of 1Epidemiology and 2Health Policy and Management, Harvard School of Public Health, Divisions of 3General Medicine and 4Infectious Diseases, Massachusetts General Hospital, 5Division of Infectious Diseases, Brigham and Woman’s Hospital, 6Harvard Medical School Center for AIDS Research, 7Departments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts; and 8Department of Health Policy and Administration, Yale School of Medicine, New Haven, Connecticut
Background.
Antiretroviral therapy (ART) reduces human immunodeficiency virus (HIV) RNA load and the probability of transmitting HIV to an HIV‐uninfected partner. However, the potential reduction in secondary transmission associated with ART may be offset by the longer duration of infectiousness.
Methods.
To estimate the effects of ART on the secondary transmission of HIV among men who have sex with men, we used a previously published state‐transition model of HIV disease to simulate the clinical and virologic course of HIV infection among 2 cohorts of men who have sex with men: (1) a cohort of individuals who were not receiving ART and (2) a cohort of individuals treated with US guideline–concordant ART. The model tracked the number of acts of unprotected insertive anal intercourse, transmission risk per act as determined by HIV RNA level, and the number of secondary cases generated in each cohort.
Results.
The estimated mean number of secondary transmissions from an HIV‐infected individual after 10, 20, and 30 years of infection were 1.9, 2.5, and 2.5, respectively, in the untreated cohort, compared with 1.4, 1.8, and 2.3, respectively, in the treated cohort. The total number of transmissions for the treated cohort began to exceed the total number of transmissions for the untreated cohort 33 years after infection; over the entire course of infection, treatment with ART led to a 23% increase in secondary infections. All estimates of the impact of ART on secondary transmission were sensitive to changes in risk behaviors.
Conclusions.
These results suggest that ART must be accompanied by effective HIV‐related risk reduction interventions. Programs that target prevention to decrease further HIV transmission are crucial to epidemic control.
Received 25 October 2006; accepted 5 January 2007; electronically published 9 March 2007.
Reprints or correspondence: Dr. Alethea W. McCormick, Dept. of Epidemiology, 677 Huntington Ave., Boston, MA 02115 (
amccormi@hsph.harvard.edu).
Cited by
David P Wilson. (2009) Modelling Based on Australian HIV Notifications Data Suggests Homosexual Age Mixing Is Primarily Assortative.
JAIDS Journal of Acquired Immune Deficiency Syndromes 51:3, 356-360
Online publication date: 1-Aug-2009.
CrossRef David P. Wilson, Alexander Hoare, David G. Regan, Matthew G. Law. (2009) Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men.
Sexual Health 6:1, 19
Online publication date: 1-Feb-2009.
CrossRef T. Déirdre Hollingsworth, Roy M. Anderson, and Christophe Fraser. (2008) HIV-1 Transmission, by Stage of Infection.
The Journal of Infectious Diseases 198:5, 687-693
Online publication date: 1-Sep-2008.
Lisa R. Metsch, Margaret Pereyra, Shari Messinger, Carlos del Rio, Steffanie A. Strathdee, Pamela Anderson‐Mahoney, Ellen Rudy, Gary Marks, and Lytt Gardner, for the Antiretroviral Treatment and Access Study (ARTAS) Study Group. (2008) HIV Transmission Risk Behaviors among HIV‐Infected Persons Who Are Successfully Linked to Care.
Clinical Infectious Diseases 47:4, 577-584
Online publication date: 15-Aug-2008.
Joshua A Salomon, Daniel R Hogan. (2008) Evaluating the impact of antiretroviral therapy on HIV transmission.
AIDS 22:Suppl 1, S149-S159
Online publication date: 1-Aug-2008.
CrossRef Viviane D. Lima, Karissa Johnston, Robert S. Hogg, Adrian R. Levy, P. Richard Harrigan, Aranka Anema, and Julio S. G. Montaner. (2008) Expanded Access to Highly Active Antiretroviral Therapy: A Potentially Powerful Strategy to Curb the Growth of the HIV Epidemic.
The Journal of Infectious Diseases 198:1, 59-67
Online publication date: 1-Jul-2008.
Frances H. Priddy, Deborah Brown, James Kublin, Kathleen Monahan, David P. Wright, Jacob Lalezari, Steven Santiago, Michael Marmor, Michelle Lally, Richard M. Novak, Stephen J. Brown, Priya Kulkarni, Sheri A. Dubey, Lisa S. Kierstead, Danilo R. Casimiro, Robin Mogg, Mark J. DiNubile, John W. Shiver, Randi Y. Leavitt, Michael N. Robertson, Devan V. Mehrotra, and Erin Quirk, for the Merck V520‐016 Study Group. (2008) Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B
gag/pol/nef Vaccine in Healthy Adults.
Clinical Infectious Diseases 46:11, 1769-1781
Online publication date: 1-Jun-2008.
David P. Wilson. (2007) Australian migration policy of HIV-infected individuals requires renewed discussions.
Australian and New Zealand Journal of Public Health 31:4, 385-386
Online publication date: 1-Sep-2007.
CrossRef Kenneth A Freedberg, Nagalingeswaran Kumarasamy, Elena Losina, Anitha J Cecelia, Callie A Scott, Nomita Divi, Timothy P Flanigan, Zhigang Lu, Milton C Weinstein, Bingxia Wang, Aylur K Ganesh, Melissa A Bender, Kenneth H Mayer, Rochelle P Walensky. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
AIDS 21:Suppl 4, S117-S128
Online publication date: 1-Aug-2007.
CrossRef